Skip to main content
  • Clinical Trials
Menu
Home
SPR
  • Healthcare Professionals
    • SPRINT® PNS System
      • Overview
      • Product Details
    • Clinical Evidence
    • Video Resources
    • Reimbursement
    • Education
    • Safety Information
    • MRI Safety Information
  • Patients & Caregivers
    • SPRINT® PNS System
      • Why SPRINT?
      • How It Works
      • What To Expect
      • Helpful FAQs
      • Safety Information
      • MRI Safety Information
    • Resources
      • Overview
      • Instructional Videos
      • Patient Stories
      • Recursos para pacientes
      • Clinical Evidence
  • About Us
    • About SPR
    • Leadership
    • Company Credo
  • News
  • Events
  • Careers
    • Overview
    • Job Listing
  • Contact Us

Press Releases

Breadcrumb

  1. Home
  2. Press Releases

All Press Releases

SPR News Placeholder SPR News Placeholder

SPR awarded $6M contract from the United States Department of Defense to advance non-opioid pain relief therapy

Press releases + media
SPR News Placeholder SPR News Placeholder

SPR appoints Michael P. Chuisano to Board of Directors

Press releases + media
SPR News Placeholder SPR News Placeholder

SPR names Dave Youngberg Vice President of Sales

Press releases + media

Pagination

  • Previous page ‹
  • Page1
  • Page2
  • Page3
  • Page4
  • Current page5
  • Healthcare Professionals
    • SPRINT® PNS System
      • Overview
      • Product Details
    • Clinical Evidence
    • Video Resources
    • Reimbursement
    • Education
    • Safety Information
    • MRI Safety Information
  • Patients & Caregivers
    • SPRINT® PNS System
      • Why SPRINT?
      • How It Works
      • What To Expect
      • Helpful FAQs
      • Safety Information
      • MRI Safety Information
    • Resources
      • Overview
      • Instructional Videos
      • Patient Stories
      • Recursos para pacientes
      • Clinical Evidence
  • About Us
    • About SPR
    • Leadership
    • Company Credo
  • News
  • Events
  • Careers
    • Overview
    • Job Listing
  • Contact Us
  • CPRA Requests
  • Consumer Health Data Request Form
  • Compliance
  • FCOI Policy
  • MRI Safety Information
  • Patent Information
  • Product Terms and Conditions
  • Safety Information
  • Trademarks
  • Billing Portal
Home
  • Consumer Health Data and Information Privacy Policy
  • Terms of Use
Visit us on Facebook
Visit us on Twitter
Visit us on Instagram
Visit us on YouTube
Visit us on LinkedIn

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only. 

View references for support of all claims.

Product and brand names/logos are registered or common law trademarks of SPR.

© 2025 SPR. All Rights Reserved.